Clinical Evidence
254 results
HDx therapy enabled by Theranova
#2513 Effect of hemodialysis with medium cut-off versus high-flux membranes on endothelial function of chronic kidney disease patients
HDx therapy enabled by Theranova
#2668 Superior biocompatibility of regional citrate anticoagulation compared to heparin during expanded hemodialysis with Theranova membrane
HDx therapy enabled by Theranova
#3230 Characteristics of protein loss with medium cut-off membranes compared to high flux membranes
HDx therapy enabled by Theranova
#3472 Preliminary data from mother HDx study: a multicentre open-label RCT study to explore the morbimortality with the Theranova HDx vs OL-HDF
HDx therapy enabled by Theranova
#6648 Long term effect of medium cut-off dialyzer on middle uremic toxins
PD
A 3-Year, Prospective, Randomized, Controlled Study on Amino Acid Dialysate in Patients on CAPD - Li FK, et al.
HDx therapy enabled by Theranova
A Budget Impact Model (BIM) for Expanded Haemodialysis (HDx) vs. High-Flux Haemodialysis (HF-HD) in Two Major Public Health Sectors, Kingdom of Saudi Arabia (KSA)
HDx therapy enabled by Theranova
A comparison between the most used new medium cut-off membranes in removal of medium molecules
PD
A controlled trial of two biocarbonate-containing dialysis fluids for CAPD - final report - Coles GA, et al.
HDx therapy enabled by Theranova
A Global Study Assessing Albumin Levels on Expanded Hemodialysis
HD
A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study - Meijers B, et al.
HDx therapy enabled by Theranova
A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear)
Vantive is a trademark of Vantive Health LLC or its affiliates.